About Healthonomix
Healthonomix helps digital health companies generate economic evidence to differentiate their product and get it adopted.
Most digital health companies think economic evidence is something you produce once, for regulators.
We think differently.
Economic evidence is the language that health systems, payers, investors, and patients use to evaluate whether a digital health product is worth their money.
Without it, the best technology in the world stalls at procurement, loses credibility with investors, or fails to convince the clinicians who are paid to recommend it.
The same rigorous economic foundation can, and should, serve four distinct audiences:
Business to Regulator/Payer
Regulators and Payers need to see clinical value and cost-effectiveness before approving and reimbursing.
Cost-effectiveness analysis involving QALY calculations, budget impact models. The NICE/HTA world. Most people stop here.
Business to Business
Healthcare Providers with commissioners who need to understand ROI and efficiency gains before committing budget.
Prove cost savings at a service level. Commissioners need a different case than NICE does.
Business to Investor
Investors need evidence of commercial viability and reimbursement credibility before writing a cheque.
Market sizing, willingness-to-pay evidence, reimbursement pathway credibility. Evidence that de-risks the commercial thesis.
Business to Consumer
Patients and consumers need to trust that the outcomes behind a product is real.
Value framing, outcomes that matter to individuals, not just systems. Increasingly relevant as self-pay digital health grows.
The evidence you need for each audience looks different, but the strategy behind it is similar, ultimately people respond to value.
Proving economic value isn't just for regulators. It's the case you make to commissioners. The credibility you show investors. The proof you give patients.
Digital health is producing genuinely transformative technology.
But transformation only follows reimbursement, and reimbursement follows evidence.
Digital health companies will invest heavily in building their product, but won't invest in building the economic case that gets it adopted at scale.
It needs four entirely different conversations.
Most companies only ever do one.
We help them do all four.
Ollie Curtis - Founder & Director
I'm a health economist and market access strategy consultant specialising in digital health. My background spans the entire clinical development lifecycle, from Phase I to Market Access. I specialise in economic evaluation, market access strategy, and HTA (the rigorous end of health economics where standards and scrutiny are high).
I founded Healthonomix while working as a management consultant in London, working across digital and traditional health technologies. I've built economic models that have gone through NICE appraisals, developed strategic dossiers that have got health technologies approved and funded across UK and European markets, and I've worked directly with founders and commercial leads navigating access and reimbursement for the first time.
Most economists don't understand how digital health technologies are built, evaluated, and bought. Most digital health consultants don't have the technical grounding to build evidence that holds up to scrutiny. I sit in the gap between those two worlds.
I love all things
Digital Health
I write regularly on digital health, HTA, and the evolving market access landscape for healthtech/digital health. If you want to follow the thinking, the Insights Hub is the place to start.
Find out more about
Healthonomix
Request our pitch deck below
Let’s create something extraordinary together
Schedule a free consultation to discuss the best approach for your product